Pudendal NeuralgiapelvicpainNCT05531500
Patient Reported Outcomes Following Interventional Procedures in Pelvic Pain
A study testing Injection and Radiofrequency in people with Pudendal Neuralgia, run by Assiut University.
Trial summary
The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Pudendal Neuralgia
- What is being tested?
- Injection and Radiofrequency
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 9 Sep 2022to 30 May 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with chronic pain> 6 months
- Patients aged > 18years
- Patients with unilateral or bilateral regional pelvic pain withpudendal irritation diagnosed by a pain clinician and clinically indicated to undergo pudendal nerve block by a consultant experienced in the field.
Who cannot join
- Known concurrent neurological or neurodegenerative disease, including those with impaired neurotransmission e.g. myasthenia gravis, multiple sclerosis, spinal cord injury etc
- Pelvic surgery is expected within 3 months
- Breastfeeding or pregnant women
- Known current pelvic/pelvic organ infection or malignancy (Red flags)
- Concurrent radiotherapy treatment to pelvis
- Allergy/sensitivity to lidocaine anaesthetic or/ and corticosteroids therapy
- Contraindication to receive a Pudendal nerve block eg high risk of bleeding
- Active psychiatric or mental conditions ▪ Other uncontrolled medical condition
Trial locations and contacts
No sites are listed yet.
About this study
The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management.
Read the detailed description
The aim of this study is toillustrate whether pulsed radiofrequency treatment is safe and effective intreating the chronic perineal pain associated with PN or pudendal nerve compression; and whether it can be used as an integral part of its multidisciplinary managementBased on literature, the prevalence of Chronic Pelvic Pain (CPP) in general population ranges between 5.7% and 26.6%(Ahangari, 2014). There are many countries and regions with no published data in the field of CPP (Ahangari, 2014). CPP is a great burden to the patients and the healthcare systems (Latthe et al., 2006). About £154 million was the estimated cost of treatment for the women who suffer from CPP per year (Cheong and William Stones, 2006). CPP affects one's movement and their posture due to the secondary hyperalgesia in the pelvic muscles leading to diminished proprioception. About 50%- 70% of women with CPP have limitation on their daily activity(Ahangari, 2014). PN occurs in men, but the incidence/prevalence is not well studied. The principle therapy for chronic neuropathic pain is to eliminate the underlying causes of the pain (Belgrade, 2003), for PN this may involve surgical decompression. Pharmacotherapy and physiotherapy are two different options for treatment of neuropathic pain but they each come with limitations and drawbacks. Different techniques for pudendal nerve block have been described for managing PN but they have complications that may be serious such, vascular injury or intravascular injection with toxicity. The indication of surgery is in patients with failure of conservative treatment or other PNB techniques / modalities and includes decompression or neuromodulation.
Type of the study: A retrospective randomized controlled study Study Setting: University college London hospital
Sample Size Calculation:
Sample size calculation was carried out using G*Power 3 software (Faul et al., 2007). A calculated minimum sample of the cases is 60 patients, 30 in each group.
Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):
Total number of the cases is 60 patients, 30 in each group.
Intervention(s):
- Informed written consent: - A copy of the signed Informed Consent form will be given to the participant. The original signed form will be retained at the study site and a copy placed in the medical notes.
- The patient is placed in the prone position
- The ischial spine is then located using fluoroscopic X ray.
- Aseptic cleaning of the skin in the target area
- Patient will randomly be allocated to the control group receiving steroid and local anaesthetic injection or treatment group receiving pulsed radiofrequency treatment and local anaesthetic. Randomisation will be performed using sealed envelopes. I. Local anaesthetic and corticosteroid injection (control group) ▪ Under X-Ray guidance, the Needle (22G 5-10 cm insulated radiofrequency needle) is advanced perpendicular to the skin and placed transgluteally, directly avoiding the adjacent sciatic nerve at either the extremity of the ischial spine between the sacrotuberous and sacrospinous ligaments.
- Sensory Electrostimulationis used to identify the nerve. For the motor stimulation, a unilateral contraction of the anal sphincter indicates that the inferior anal nerve had been stimulated while for the sensory stimulation, a sensation of tingling or numbness in the perineal region may be felt by the patient.
- Contrast injected to avoid intravascular injection. A blinded operator sets the radiofrequency machine for a timer alert at five minutes.
- After confirming the exact location of the needle tip, 4 mL of 1% lidocaine and 3.3 of dexamethasone in 1 mL are injected. II. Pulsed radiofrequency (Treatment/intervention group)
- Needle is placed using the same technique as above and contrast medium is injected.
- Lesion: - Radiofrequency current will be applied for 5 minutes, 120 ms, at 2 Hz, with maximum tissue temperature increased to 42°C. (usually not felt by the patient)
- 4 mL of 1% lidocaine and 1 mL of NaCl .9% are injected.
- Post procedure instructions:- ▪ Standard post procedure monitoring for 1 hour in theatre recovery, including treatment of nausea/vomiting and localized pain with standard intravenous/oral medication.
- Immediate adverse events reporting.
- Standard hospital post procedure instructions
Research outcome measures:
- Primary Endpoint: Reduction in at least 1.5 point pain as measured by Numerical Rating Scale Secondary Endpoint A. NRS at 0, 1 and 12 weeks B Quality of Life Assessment at baseline, week 1, week 6 and week 12 a. EDQ5-5L b. SF-12 c. Brief Pain Inventory d. Global response Assessment C. Mood assessment at baseline, week 6 and week 12
- Pain Catastrophising Questionnaire b. Beck Depression Inventory II c. Hamilton Anxiety Rating Scale d. Sexual function assessment (questionnaire) at baseline, weeks 6 and 12 e. Lower urinary tract symptom assessment at baseline, weeks 6 and 12 f. Bristol Female Lower Urinary Tract Symptoms (BFLUTS-SF) g Review of pain medication use at weeks 6, 12 compared to baseline. h. Assessment of all patients against Nantes criteria at baseline 2.5-Data management and analysis (Details needed): Data collection. Telephone review - Week 1
- Telephone review in 1 week to assess for complication and side effcte profile.
- Global pelvic pain NRS scores over telephone.
- Adverse events reporting.
- Telephone review at 6 weeks and 12 weeks
- review pelvic pain
- Questionaires: global pelvic pain, QoL and function
- Medication review <!-- -->
- S - Study/Statistical design (e.g. randomised controlled trial, case control study, pilot study):
- Prospective
- Parallel group ( 2 different groups)
- No active Control
- Randomized
- Single blinded
- multicentric study (at UCLH center) Statistical methods:
- All data will be collected and cleaned by Excel program then will be analyzed with SPSS software (Statistical Package for the Social Sciences, version 16, SSPS Inc, and Chicago, USA). ii. Continuous parametric data between two groups, two sample T test will be used. iii. Continuous parametric data between more than 2 groups, ANOVA test will be used. iv. Descriptive statistics will be done in the form of mean and standard error (SE).
- Frequency of qualitative variables and Chi-square test will be done. vi. In Categorical data, Chi-squared test will be used.
- Conditions
- Pudendal Neuralgia
- Being tested
- Injection, Radiofrequency
- Keywords
- Pelvic pain
- Medical subject headings
- Pudendal Neuralgia, Pelvic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InjectionDrug
Injection of local anesthetic + steroids
RadiofrequencyDevice
Application of radiofrequency on the diseased nerve
| Study group | Role | What they receive |
|---|---|---|
| Injection | Other | Injection of local anesthetic and steroid to the diseased nerve Receives: Drug: Injection |
| Radiofrequency | Other | Application of radiofrequency to the diseased nerve Receives: Device: Radiofrequency |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain score
Pain score value from 1 to 10 reported by each individual patient following inter vention
Measured: 6months 1 year after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2022
- Study start9 Sep 2022 (estimated)
- Primary completion30 Apr 2023 (estimated)
- Study completion30 May 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pudendal NeuralgiaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- parallel groups of different intervention
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Medhat Farghaly, Assiut University
- Investigators
- Medhat SA Farghaly, master, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05531500
- Sponsor's protocol ID
- pelvic pain outcome
- Acronym
- pelvicpain
- Status last verified
- Sep 2022
- First submitted
- 4 Sep 2022
- Last updated
- 10 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Reported Outcomes Following Interventional Procedures in Pelvic Pain
- ClinicalTrials.gov ID
- NCT05531500
- Acronym / sponsor ID
- pelvicpain / pelvic pain outcome
- Conditions
- Pudendal Neuralgia
- Keywords
- Pelvic pain
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 9 Sep 2022 (estimated)
- Primary completion
- 30 Apr 2023 (estimated)
- Study completion
- 30 May 2023 (estimated)
- First posted
- 8 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management.
Detailed description
The aim of this study is toillustrate whether pulsed radiofrequency treatment is safe and effective intreating the chronic perineal pain associated with PN or pudendal nerve compression; and whether it can be used as an integral part of its multidisciplinary managementBased on literature, the prevalence of Chronic Pelvic Pain (CPP) in general population ranges between 5.7% and 26.6%(Ahangari, 2014). There are many countries and regions with no published data in the field of CPP (Ahangari, 2014). CPP is a great burden to the patients and the healthcare systems (Latthe et al., 2006). About £154 million was the estimated cost of treatment for the women who suffer from CPP per year (Cheong and William Stones, 2006). CPP affects one's movement and their posture due to the secondary hyperalgesia in the pelvic muscles leading to diminished proprioception. About 50%- 70% of women with CPP have limitation on their daily activity(Ahangari, 2014). PN occurs in men, but the incidence/prevalence is not well studied. The principle therapy for chronic neuropathic pain is to eliminate the underlying causes of the pain (Belgrade, 2003), for PN this may involve surgical decompression. Pharmacotherapy and physiotherapy are two different options for treatment of neuropathic pain but they each come with limitations and drawbacks. Different techniques for pudendal nerve block have been described for managing PN but they have complications that may be serious such, vascular injury or intravascular injection with toxicity. The indication of surgery is in patients with failure of conservative treatment or other PNB techniques / modalities and includes decompression or neuromodulation.
Type of the study: A retrospective randomized controlled study Study Setting: University college London hospital
Sample Size Calculation:
Sample size calculation was carried out using G*Power 3 software (Faul et al., 2007). A calculated minimum sample of the cases is 60 patients, 30 in each group.
Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):
Total number of the cases is 60 patients, 30 in each group.
Intervention(s):
- Informed written consent: - A copy of the signed Informed Consent form will be given to the participant. The original signed form will be retained at the study site and a copy placed in the medical notes.
- The patient is placed in the prone position
- The ischial spine is then located using fluoroscopic X ray.
- Aseptic cleaning of the skin in the target area
- Patient will randomly be allocated to the control group receiving steroid and local anaesthetic injection or treatment group receiving pulsed radiofrequency treatment and local anaesthetic. Randomisation will be performed using sealed envelopes. I. Local anaesthetic and corticosteroid injection (control group) ▪ Under X-Ray guidance, the Needle (22G 5-10 cm insulated radiofrequency needle) is advanced perpendicular to the skin and placed transgluteally, directly avoiding the adjacent sciatic nerve at either the extremity of the ischial spine between the sacrotuberous and sacrospinous ligaments.
- Sensory Electrostimulationis used to identify the nerve. For the motor stimulation, a unilateral contraction of the anal sphincter indicates that the inferior anal nerve had been stimulated while for the sensory stimulation, a sensation of tingling or numbness in the perineal region may be felt by the patient.
- Contrast injected to avoid intravascular injection. A blinded operator sets the radiofrequency machine for a timer alert at five minutes.
- After confirming the exact location of the needle tip, 4 mL of 1% lidocaine and 3.3 of dexamethasone in 1 mL are injected. II. Pulsed radiofrequency (Treatment/intervention group)
- Needle is placed using the same technique as above and contrast medium is injected.
- Lesion: - Radiofrequency current will be applied for 5 minutes, 120 ms, at 2 Hz, with maximum tissue temperature increased to 42°C. (usually not felt by the patient)
- 4 mL of 1% lidocaine and 1 mL of NaCl .9% are injected.
- Post procedure instructions:- ▪ Standard post procedure monitoring for 1 hour in theatre recovery, including treatment of nausea/vomiting and localized pain with standard intravenous/oral medication.
- Immediate adverse events reporting.
- Standard hospital post procedure instructions
Research outcome measures:
- Primary Endpoint: Reduction in at least 1.5 point pain as measured by Numerical Rating Scale Secondary Endpoint A. NRS at 0, 1 and 12 weeks B Quality of Life Assessment at baseline, week 1, week 6 and week 12 a. EDQ5-5L b. SF-12 c. Brief Pain Inventory d. Global response Assessment C. Mood assessment at baseline, week 6 and week 12
- Pain Catastrophising Questionnaire b. Beck Depression Inventory II c. Hamilton Anxiety Rating Scale d. Sexual function assessment (questionnaire) at baseline, weeks 6 and 12 e. Lower urinary tract symptom assessment at baseline, weeks 6 and 12 f. Bristol Female Lower Urinary Tract Symptoms (BFLUTS-SF) g Review of pain medication use at weeks 6, 12 compared to baseline. h. Assessment of all patients against Nantes criteria at baseline 2.5-Data management and analysis (Details needed): Data collection. Telephone review - Week 1
- Telephone review in 1 week to assess for complication and side effcte profile.
- Global pelvic pain NRS scores over telephone.
- Adverse events reporting.
- Telephone review at 6 weeks and 12 weeks
- review pelvic pain
- Questionaires: global pelvic pain, QoL and function
- Medication review <!-- -->
- S - Study/Statistical design (e.g. randomised controlled trial, case control study, pilot study):
- Prospective
- Parallel group ( 2 different groups)
- No active Control
- Randomized
- Single blinded
- multicentric study (at UCLH center) Statistical methods:
- All data will be collected and cleaned by Excel program then will be analyzed with SPSS software (Statistical Package for the Social Sciences, version 16, SSPS Inc, and Chicago, USA). ii. Continuous parametric data between two groups, two sample T test will be used. iii. Continuous parametric data between more than 2 groups, ANOVA test will be used. iv. Descriptive statistics will be done in the form of mean and standard error (SE).
- Frequency of qualitative variables and Chi-square test will be done. vi. In Categorical data, Chi-squared test will be used.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- parallel groups of different intervention
| Arm | Type | Receives |
|---|---|---|
| Injection | Other | Drug: InjectionInjection of local anesthetic and steroid to the diseased nerve |
| Radiofrequency | Other | Device: RadiofrequencyApplication of radiofrequency to the diseased nerve |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients with chronic pain> 6 months
Key exclusion criteria (8 listed)
- Known concurrent neurological or neurodegenerative disease, including those with impaired neurotransmission e.g. myasthenia gravis, multiple sclerosis, spinal cord injury etc
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InjectionInjection of local anesthetic + steroids | Drug | Injection |
| RadiofrequencyApplication of radiofrequency on the diseased nerve | Device | Radiofrequency |
Primary outcome
Pain score
Time frame: 6months 1 year after intervention
Pain score value from 1 to 10 reported by each individual patient following inter vention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2022.
- https://link.springer.com/article/10.1007/s11608-006-0064-2Link provided by the sponsor.
- https://connect.springerpub.com/content/sgrcl/5/3/97.abstractLink provided by the sponsor.
- https://journals.lww.com/anesthesia-analgesia/FullText/2013/12000/The\_Effectiveness\_of\_Pudendal\_Nerve\_Block\_Versus.21.aspxLink provided by the sponsor.
- https://www.diva-portal.org/smash/record.jsf?pid=diva2:770659Link provided by the sponsor.
- https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-6-177Link provided by the sponsor.
- https://books.google.com/books?hl=ar\&lr=\&id=FMU0AwAAQBAJ\&oi=fnd\&pg=PP1\&dq=+Chestnut+D,+Polley+L,+TsenL,Wong+C,+eds.+Chestnut%E2%80%99s+obstetric+anesthesia:+Principles+and+practice.\&ots=czX9TVymak\&sig=AVjCTsd6bT3TEKhgQ5BoBIJZuXgLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Pudendal Neuralgia
Active, not recruiting
Positioning for Hip Arthroscopic Surgery to Reduce Postoperative Numbness
Hip Osteoarthritis, Hip Injuries
Active, not recruiting
Pudendal Nerve Block With Articaine and Triamcinolone for Pudendal Neuralgia
Pudendal Neuralgia Pudendal Nerve Entrapment Chronic Pelvic Pain
RecruitingObservational study
Decompression of Pudendal and Inferior Cluneal Nerves Using Robot-assisted Laparoscopy for Entrapment Neuralgias : the X-DECO Study
Pudendal Neuralgia
Recruiting
Conventional Versus High-Voltage Long-Duration Pulsed Radiofrequency of the Pudendal Nerve
Pudendal Neuralgia
RecruitingPhase 3
Evaluation of the Efficacy of Therapeutic Infiltrations of the Pudendal Nerve, Performed Under Neurostimulation on Pain, 1 Month After an Infiltration of Local Anaesthetic, in the Treatment of Pudendal Neuralgia.
Pudendal Neuralgia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medhat SA Farghaly, master principal investigator
Assiut University
Questions about this trial
What is this clinical trial studying?
A study testing Injection and Radiofrequency in people with Pudendal Neuralgia, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Medhat SA Farghaly, Master (2001095105568, medhatsradwan@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain score (time frame: 6months 1 year after intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2022.